Find the Right Model for Your Preclinical Investigation
The BarneyOI Cancer Model Database® will help you source clinically relevant North American-derived cancer models from the Certis Tumor Bank. Whether your ideal model is naïve or pretreated, primary or metastatic, orthotopic or heterotopic PDX or cell culture, you’ll find characterization data that faithfully represents each model’s unique genetic and biologic features.
This oncology tumor bank database contains more than 500 growth curves, over 40 cancer subtypes, 18 implantation sites and 17 preset filters.
Search, Filter and Sort From One Central, Intuitive, Responsive User-interface
- Fine-tune your custom keyword search with 17 preset filters
- Drill down into genomic profiles using gene filters. Extensive genomic analyses include expression levels, mutations, gene fusions, and copy number variations.
- Compare gene expression results to matched disease-free tissue (i.e., matched normals).
- Obtain a detailed model profile of patient and tumor model characteristics, with links to related xenograft tumor models.
- View interactive graphical representations of model sets, including growth curves, histology and MRI.
- Export and share your selected analysis for your preclinical oncology investigation.
Watch this video that shows users how to optimally navigate BarneyOI and take advantage of enhanced search features to find the right fit from the Certis Tumor Bank — a growing collection of highly characterized, richly annotated, and low-passage patient-consented PDX oncology models and tumor cell lines.
Studying Rare or Complex Cancers?
Ask BarneyOI.
Easily search and select in vivo and in vitro models from the Certis Tumor Bank, which is comprised of a wide range of disease states and model types (orthotopic and subcutaneous PDX, PDX-derived cell lines and humanized mouse models) — including treatment-naïve, heavily pretreated, metastatic, advanced-stage and drug-resistant cancers.
Your Translational Partner
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.